%PDF-1.4
%
62 0 obj
<>
endobj
59 0 obj
<>
endobj
101 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-12-03T17:30:44Z
2024-03-28T14:08:40-07:00
QuarkXPressª: AdobePS 8.6 (219)
2024-03-28T14:08:40-07:00
application/pdf
Heather
2001-408.may02
uuid:c4d9d04a-1dd1-11b2-0a00-7108275dc400
uuid:c4d9d04d-1dd1-11b2-0a00-810000000000
endstream
endobj
48 0 obj
<>
endobj
49 0 obj
<>
endobj
63 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
1 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
4 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
7 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
15 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
23 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
26 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
127 0 obj
[131 0 R]
endobj
128 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.06 612 -792 re
W n
BT
/CS0 cs 0 0 0 1 scn
/GS1 gs
/TT0 1 Tf
0.02499 Tw 8 0 0 8 74.4 714.5293 Tm
(articular index for the assessment of joint tenderness in patients)Tj
0 -1.25 TD
(with rheumatoid arthritis. Q J Med 1968;37:393-406.)Tj
-2.175 -1.25 Td
[(17.)-875 (van der Heijde DM, van \221t Hof M, van Riel PL, et al. Judging)]TJ
2.175 -1.25 Td
(disease activity in clinical practice in rheumatoid arthritis: first ste\
p)Tj
T*
[(in the development of a disease activity score. )54.8 (Ann Rheum Dis)]TJ
0 Tw T*
(1990;49:916-20.)Tj
0.0072 Tw -2.175 -1.25 Td
[(18.)-875 (Lark )-17.7 (MW)91.8 (, W)79.8 (alakovits )-17.8 (LA, )-17.8 (Shah TK, V)111.1 (anmiddlesworth )-17.8 (J, )-17.7 (Cameron)]TJ
0.0249 Tw 2.175 -1.25 Td
[(PM, Lin )17.7 (TY)128.9 (. Production and purification of prostromelysin and)]TJ
T*
(procollagenase from IL-1 beta-stimulated human gingival )Tj
T*
[(fibroblasts. Connect )17.8 (T)34.9 (issue Res 1990;25:49-65.)]TJ
-0.00011 Tc -2.175 -1.25 Td
[(19.)-875.1 (van Leeuwen MA, van Rijswijk MH, Marrink J, )17.7 (W)79.7 (estra J, de Jong)]TJ
2.175 -1.25 Td
[(HJ. CRP)-238.2 (measurements in rheumatic disorders. Protides of the)]TJ
0 Tc T*
(biological fluids 1986;34:315-8.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(20.)-875.1 (Stenger )54.8 (AA, van Leeuwen MA, Houtman PM, et al. Early ef)17.7 (fective)]TJ
0 Tc 2.175 -1.25 Td
(suppression of inflammation in rheumatoid arthritis reduces )Tj
T*
[(radiographic progression. Br J Rheumatol 1998;37:1)36.9 (157-63.)]TJ
-0.00011 Tc -2.175 -1.25 Td
[(21.)-875.1 (Gabay C, Kushner I. )54.8 (Acute-phase proteins and other systemic)]TJ
0 Tc 2.175 -1.25 Td
(responses to inflammation. N Engl J Med 1999;340:448-54.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(22.)-875.1 (Cheung NT)73.9 (, Mattey DL, Dawes PT)73.9 (, )17.7 (T)69.7 (aylor DJ. Serum pro-matrix)]TJ
0 Tc 2.175 -1.25 Td
(metalloproteinase 3 in rheumatoid arthritis: a reflection of local or)Tj
T*
[(systemic inflammation? )54.9 (Arthritis Rheum 1996;39:884-6.)]TJ
-2.175 -1.25 Td
[(23.)-875 (Emery P)110.8 (, Salmon M. Early rheumatoid arthritis: time to aim for)]TJ
2.175 -1.25 Td
[(remission? )54.9 (Ann Rheum Dis 1995;54:944-7.)]TJ
-2.175 -1.25 Td
[(24.)-875 (Epstein FH. Nuclear factor)19.8 (-kB. )54.8 (A)-219.8 (pivotal transcription factor in)]TJ
2.175 -1.25 Td
(chronic inflammatory diseases. N Engl J Med 2001;336:1066-71.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(25.)-875.1 (Han Z, Boyle DL, Manning )54.8 (AM, Firestein GS. )54.8 (AP-1 and NF-kappa)]TJ
0 Tc 2.175 -1.25 Td
(B regulation in rheumatoid arthritis and murine collagen-induced)Tj
-0.02991 Tw T*
[(arthritis. Autoimmunity )-54.9 (1998;28:197-208.)]TJ
0.02499 Tw -2.175 -1.25 Td
[(26.)-875 (Bondeson J, Brennan F)79.8 (, Foxwell B, Feldmann M. Ef)17.8 (fective )]TJ
-0.00011 Tc 2.175 -1.25 Td
(adenoviral transfer of IkBa into human fibroblasts and)Tj
0 Tc T*
(chondrosarcoma cells reveals that the induction of matrix)Tj
T*
(metalloproteinases and proinflammatory cytokines is nuclear)Tj
T*
[(factor)19.8 (-kB dependent. J Rheumatol 2000;27:2078-89.)]TJ
-2.175 -1.25 Td
[(27.)-875 (W)79.8 (ahl C, Liptay S, )54.9 (Adler G, Schmid RM. Sulfasalazine: a potent and)]TJ
2.175 -1.25 Td
(specific inhibitor of nuclear factor kappa B. J Clin Invest)Tj
0 Tw T*
[(1998;101:1)36.9 (163-74.)]TJ
-0.00011 Tc 0.02499 Tw 30.825 43.75 Td
[(28.)-875.1 (Martel-Pelletier J, Cloutier JM, Pelletier JP)110.7 (. In vivo ef)17.7 (fects of)]TJ
0 Tc 2.175 -1.25 Td
(antirheumatic drugs on neutral collagenolytic proteases in human)Tj
T*
(rheumatoid arthritis cartilage and synovium. J Rheumatol)Tj
0 Tw T*
[(1988;15:1)36.9 (198-204.)]TJ
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(29.)-875.1 (Firestein GS, Paine MM, Boyle DL. Mechanisms of methotrexate)]TJ
0 Tc 2.175 -1.25 Td
(action in rheumatoid arthritis. Selective decrease in synovial )Tj
T*
[(collagenase gene expression. )54.9 (Arthritis Rheum 1994;37:193-200.)]TJ
-2.175 -1.25 Td
[(30.)-875 (Genestier L, Paillot R, Quemeneur L, Izeradjene K, Revillard JP)110.8 (.)]TJ
2.175 -1.25 Td
(Mechanisms of action of methotrexate. Immunopharmacology)Tj
0 Tw T*
(2000;47:247-57.)Tj
0.0249 Tw -2.175 -1.25 Td
[(31.)-875 (Firestein GS, Manning )54.8 (AM. Signal transduction and transcription)]TJ
2.175 -1.25 Td
[(factors in rheumatic disease. )54.8 (Arthritis Rheum 1999;42:609-21.)]TJ
-0.00011 Tc -2.175 -1.25 Td
[(32.)-875.1 (Brennan FM, Browne KA, Green P)91.7 (A, Jaspar JM, Maini RN,)]TJ
0 Tc 2.175 -1.25 Td
(Feldmann M. Reduction of serum matrix metalloproteinase 1 and)Tj
T*
(matrix metalloproteinase 3 in rheumatoid arthritis patients)Tj
-0.00011 Tc T*
[(following anti-tumour necrosis factor)19.7 (-alpha \(cA2\) therapy)64.8 (. Br J)]TJ
0 Tc T*
(Rheumatol 1997;36:643-50.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(33.)-875.1 (Sharif M, Salisbury C, )17.7 (T)69.7 (aylor DJ, Kirwan JR. Changes in )]TJ
0 Tc 2.175 -1.25 Td
(biochemical markers of joint tissue metabolism in a randomized)Tj
T*
(controlled trial of glucocorticoid in early rheumatoid arthritis.)Tj
T*
(Arthritis Rheum 1998;41:1203-9.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(34.)-875.1 (Ichikawa )36.8 (Y)129.1 (,)-0.1 ( )36.8 (Y)100 (amada C, Horiki )17.7 (T)73.9 (, Hoshina )36.8 (Y)129.1 (, Uchiyama M. Serum)]TJ
0 Tc 2.175 -1.25 Td
(matrix metalloproteinase-3 and fibrin degradation product levels)Tj
T*
(correlate with clinical disease activity in rheumatoid arthritis. Clin)Tj
T*
(Exp Rheumatol 1999;16:533-40.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(35.)-875.1 (Manicourt DH, Fujimoto N, Obata K, )17.7 (Thonar EJ. Levels of)]TJ
0 Tc 2.45 -1.25 Td
(circulating collagenase, stromelysin-1, and tissue inhibitor of)Tj
-0.275 -1.25 Td
(matrix metalloproteinases 1 in patients with rheumatoid arthritis.)Tj
T*
(Relationship to serum levels of antigenic keratan sulfate and)Tj
T*
[(systemic parameters of inflammation. )54.8 (Arthritis Rheum)]TJ
0 Tw T*
(1995;38:1031-9.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(36.)-875.1 (So )54.8 (A, Chamot )54.8 (AM, Peclat )17.7 (V)129.1 (, Gerster JC. Serum MMP-3 in )]TJ
0 Tc 2.175 -1.25 Td
(rheumatoid arthritis: correlation with systemic inflammation but not)Tj
T*
(with erosive status. Br J Rheumatol 1999;38:407-10.)Tj
/TT1 1 Tf
-0.00011 Tc -35.4875 -43.5681 Td
(Posthumus, et al: Serum MMP-3 and DMARD)Tj
0 Tc 0 Tw 61.4375 -0.0313 Td
(889)Tj
ET
/CS0 CS 0 0 0 1 SCN
55 54 m
559 54 l
S
0 0 0 0 scn
/GS0 gs
100.25 59.08 407.5 -10.83 re
f*
0.5 w
100.25 59.08 407.5 -10.83 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 g
/GS2 gs
/T1_0 8 Tf
120.092 51 Td
(Personal non-commercial use only. The Journal of Rheumatology Copyright\
\251 2002. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_1 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
86 0 obj
<>
endobj
106 0 obj
<>
endobj
69 0 obj
<>
endobj
65 0 obj
<>
endobj
67 0 obj
<>
endobj
80 0 obj
<>stream
HV lޛ]1|l;ܘ3xmR.C0 .>p ˁ BA!&@!%TƔ[ P8 (oJ}y Z
Gݿn?(UTػq*3;R
+^>EFp$ 9}Ҷ#wb@}zQuD_\V^cϷojĬ9ExGTDw鿀@y5@91>sWZwAn+T|u
'9Q$l$jh#Αźhpj)C35=.=,-ԣґ*mH+$6a9"y).q( ڥUOPװu8(!YkF7lIXk%F9k'H0|9ʉ_Y-rwep 1i<=gͣW;1>^UHdqNLJc{E4_c4桒;^4/:l}O[
)Dθ1ksWpUDbqX^ŭ,Wv1Z'YM:QA➄pj:Y9bL/R9G߫Rb]#섓E0u{A"Z߲wl;;sBN!,Fd"/* ezJyCkB-Uh͵>e]0{RO.;O4sI{xGD%b8bE2Gpj|1FT%Z,o5{G|*y''rLg7)R"QԉN-Z-Ҫ]ޏ&B-m[UbkUϮdZ#;(|ɘ"b&{\znba' Qfw]?'<#:wyNݙQ3'
OLSTQ*\XWr0-buqGe{5%H]f3y#sP.](?䟥)cw2TTWR\eU٦PT#SVs?hm,-[+Њl-jGo4co9W8;kw|Ӟ}! ҋK
,|wN!>?r8ʓ5EbxIm8RH zװ.xZCCxRgU:2VƷqH1T'o1ޭkǨK1%9)CB|\lvmĴnղEdӡ~Lj1l g~S(yS-=,R0{